Prognosis
Moderna to Supply Up to 500 Million Vaccine Doses to Covax
- Pact buoys global campaign, but most doses will come in 2022
- Worries for many vulnerable regions grow amid crisis in India
This article is for subscribers only.
Moderna Inc. agreed to provide as many as 500 million doses of its Covid-19 shot to the program known as Covax in a boost for the global vaccination effort, but only a small fraction of the shipments are due to arrive this year.
The U.S. drugmaker is joining developers including AstraZeneca Plc, Pfizer Inc. and Johnson & Johnson in supplying Covax, which has faced setbacks in its bid to help lower-income nations. The vaccine last week was cleared for emergency use by the World Health Organization, making it eligible for Covax.